Valuation: Geron Corporation

Market Cap 828M 719M 670M 615M 1.16B 79B 1.18B 7.89B 3.1B 39.33B 3.11B 3.04B 132B P/E 2026 *
-80.6x
P/E 2027 * 14.3x
Enterprise Value 828M 719M 670M 615M 1.16B 79B 1.18B 7.89B 3.1B 39.33B 3.11B 3.04B 132B EV / Sales 2026 *
3.53x
EV / Sales 2027 * 2.42x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-3.73%
1 week-9.15%
1 month+0.78%
3 months-16.23%
6 months-5.84%
Current year-2.27%
1 week 1.22
Extreme 1.22
1.53
1 month 1.22
Extreme 1.22
1.62
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
30/6/26 Free

Director

6,103 0.0010%
17/2/26 Fiscal year

Chief Financial Officer

1,724,855 0.2702%
17/2/26 Free

Chief Technology Officer

2,220,000 0.3478%
Change 5-day change 1-year change 3-year change Capi.($)
-3.73%-9.15%+12.17%-60.19% 828M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.49%-4.17%+32.25%+135.60% 23.47B
Weighted average by Cap. +0.22%-2.98%+28.61%+119.34%

Financials

2026 *2027 *
Net sales 234M 204M 190M 174M 329M 22.36B 334M 2.23B 877M 11.13B 880M 860M 37.32B 342M 298M 277M 254M 480M 32.68B 488M 3.27B 1.28B 16.27B 1.29B 1.26B 54.55B
Net income -10.96M -9.53M -8.87M -8.14M -15.38M -1.05B -15.62M -105M -41.03M -521M -41.17M -40.26M -1.75B 65.62M 57.04M 53.09M 48.74M 92.05M 6.26B 93.48M 626M 246M 3.12B 246M 241M 10.46B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
31/07/26 US$1.290 -3.73% 19,611,828
30/07/26 US$1.340 -4.29% 19,466,252
29/07/26 US$1.400 -3.45% 5,656,182
28/07/26 US$1.450 -2.03% 5,043,308
27/07/26 US$1.480 +4.23% 8,915,738
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.290USD
Average target price
4.250USD
Spread / Average Target
+229.46%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock